SGLT-2抑制剂对2型糖尿病患者的肾脏保护作用进展  

Renal protection of SGLT-2 inhibitors in type 2 diabetes mellitus

作　　者：张慧芳 王利杰 张程远 李桂英[3] ZHANG Hui-fang;WANG Li-jie;ZHANG Cheng-yuan(Hebei University of Engineering Clinical College of Medicine,Handan,Hebei 056000,China;不详)

机构地区：[1]河北工程大学临床医学院,河北邯郸056000 [2]兰州大学第二临床医学院,甘肃兰州730000 [3]河北工程大学附属医院,河北邯郸056000

出　　处：《实用医药杂志》2021年第6期558-563,共6页Practical Journal of Medicine & Pharmacy

摘　　要：糖尿病肾病(DKD)是2型糖尿病(T2DM)常见的、严重的微血管并发症,同时也是引起终末期肾病的重要原因。在治疗T2DM时,除了控制血糖,预防DKD的发生尤为重要。钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂是一种不依赖胰岛素水平的新型降糖药,主要通过抑制肾脏近端小管的SGLT-2蛋白减少葡萄糖重吸收而降低血糖水平。大量实验研究结果证明,SGLT-2抑制剂有独立于降血糖之外的肾脏保护作用,可延缓DKD的发生和发展。现就SGLT-2抑制剂对T2DM患者的肾脏保护作用和可能的作用机制做一综述。Diabetic kidney disease(DKD) is a common and serious microvascular complication of type 2 diabetes(T2 DM) and an important cause of end-stage renal disease. Therefore,in addition to controlling blood glucose,it is particularly important to prevent the occurrence of DKD in the treatment of T2 DM. Sodium-glucose cotransporter 2(SGLT-2) inhibitor is a new type of glucose-lowering drug that being not rely on insulin level. It mainly reduces glucose reabsorption by inhibiting sGLT-2 protein in the proximal renal tubule. A large number of experimental results have proved that SGLT-2 inhibitor has a renal protective effect independent of hypoglycemia,delays the occurrence and development of DKD. This article reviews the renal protective effects and possible mechanisms of SGLT-2 inhibitors in patients with T2 DM.

关 键 词：2型糖尿病 钠-葡萄糖协同转运蛋白-2抑制剂 糖尿病肾病 

分 类 号：R587.1[医药卫生—内分泌]